Trial Profile
Efficacy, tolerability and pharmacokinetics of GS 9451 in patients with genotype 1a or 1b hepatitis C
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Jan 2013
Price :
$35
*
At a glance
- Drugs Vedroprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 28 Sep 2012 Primary endpoint 'Viral-load' has been met.
- 03 Apr 2011 Results presented at the 46th Annual Meeting of the European Association for the Study of the Liver.
- 31 Oct 2010 New trial record